Detection of Gene Mutations in Non-small Cell Lung Cancer Cells in Blood Samples or Fine-needle Aspiration
Samples will be collected before the systemic therapy. After initiation of therapy, samples
will be collected at end of the 1st month, at the end of the 2nd month at the end of 3rd
months and once every three months thereafter concurrently with the tumor assessment such as
time of performing CT scans. In selected consented patients, peripheral blood samples will
be collected every week for the first month.
Disease status will be assessed every 2~3 months and at the end of treatment according to
RECIST criteria. If progression is not observed at the end of therapy, patients will be
assessed every 3 months until progression or further anti-cancer therapy. Progression-free
survival, overall survival and response rate will be reported.
Observational Model: Case-Only, Time Perspective: Prospective
To determine the frequency of individual genetic abnormality in advanced non-small cell lung cancer (NSCLC) patients who will commence systemic therapy.
Samples will be collected before the systemic therapy, at the end of the first three months and once every 3 months. In selected consented patients, peripheral blood samples will be collected every week for the first month.
Chih-Hsin Yang, M.D., ph.D.
National Taiwan University College of Medicine
Taiwan: Department of Health